Exilby: FDA Fast-Tracks Cannabis-Derived Painkiller Disrupting Multi-Billion-Dollar Opioid Industry

A botanically derived, non-opioid pain treatment made from cannabis is moving through regulatory review in Europe and the United States, adding to growing evidence that supported the FDA’s 2024 recommendation to reschedule cannabis to Schedule III.... By: Vicente LLP